{"doi":"10.1371/journal.ppat.1011657","title":"Pharmacological inhibition of bromodomain and extra-terminal proteins induces an NRF-2-mediated antiviral state that is subverted by SARS-CoV-2 infection","abstract":"Inhibitors of bromodomain and extra-terminal proteins (iBETs), including JQ-1, have been suggested as potential prophylactics against SARS-CoV-2 infection. However, molecular mechanisms underlying JQ-1-mediated antiviral activity and its susceptibility to viral subversion remain incompletely understood. Pretreatment of cells with iBETs inhibited infection by SARS-CoV-2 variants and SARS-CoV, but not MERS-CoV. The antiviral activity manifested itself by reduced reporter expression of recombinant viruses, and reduced viral RNA quantities and infectious titers in the culture supernatant. While we confirmed JQ-1-mediated downregulation of expression of angiotensin-converting enzyme 2 (ACE2) and interferon-stimulated genes (ISGs), multi-omics analysis addressing the chromatin accessibility, transcriptome and proteome uncovered induction of an antiviral nuclear factor erythroid 2-related factor 2 (NRF-2)-mediated cytoprotective response as an additional mechanism through which JQ-1 inhibits SARS-CoV-2 replication. Pharmacological inhibition of NRF-2, and knockdown of NRF-2 and its target genes reduced JQ-1-mediated inhibition of SARS-CoV-2 replication. Serial passaging of SARS-CoV-2 in the presence of JQ-1 resulted in predominance of ORF6-deficient variant, which exhibited resistance to JQ-1 and increased sensitivity to exogenously administered type I interferon (IFN-I), suggesting a minimised need for SARS-CoV-2 ORF6-mediated repression of IFN signalling in the presence of JQ-1. Importantly, JQ-1 exhibited a transient antiviral activity when administered prophylactically in human airway bronchial epithelial cells (hBAECs), which was gradually subverted by SARS-CoV-2, and no antiviral activity when administered therapeutically following an established infection. We propose that JQ-1 exerts pleiotropic effects that collectively induce an antiviral state in the host, which is ultimately nullified by SARS-CoV-2 infection, raising questions about the clinical suitability of the iBETs in the context of COVID-19.","journal":"PLoS Pathogens","year":2023,"id":411820,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9491,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":566946,"name":"Dylan Postmus","orcid":"0000-0002-9551-0411","position":1,"is_corresponding":false},{"id":674046,"name":"Saskia Stenzel","orcid":"0000-0003-0926-7759","position":2,"is_corresponding":false},{"id":252328,"name":"January Weiner","orcid":"0000-0003-1438-7819","position":3,"is_corresponding":false},{"id":567873,"name":"Jenny Jansen","orcid":null,"position":4,"is_corresponding":false},{"id":901043,"name":"Francisco J. Zapatero‐Belinchón","orcid":"0000-0002-2751-8411","position":5,"is_corresponding":false},{"id":55414,"name":"Ruth Olmer","orcid":null,"position":6,"is_corresponding":false},{"id":230501,"name":"Anja Richter","orcid":"0000-0001-5297-3750","position":7,"is_corresponding":false},{"id":818721,"name":"Julian Heinze","orcid":null,"position":8,"is_corresponding":false},{"id":818722,"name":"Nicolas Heinemann","orcid":null,"position":9,"is_corresponding":false},{"id":615722,"name":"Barbara Mühlemann","orcid":"0000-0002-5314-8530","position":10,"is_corresponding":false},{"id":818100,"name":"Simon Schroeder","orcid":"0000-0003-2085-767X","position":11,"is_corresponding":false},{"id":615720,"name":"Terry C. Jones","orcid":"0000-0003-1120-9531","position":12,"is_corresponding":false},{"id":234020,"name":"Marcel A. Müller","orcid":"0000-0003-2242-5117","position":13,"is_corresponding":false},{"id":57977,"name":"Christian Drosten","orcid":"0000-0001-7923-0519","position":14,"is_corresponding":false},{"id":793123,"name":"Andreas Pich","orcid":"0000-0001-8444-0940","position":15,"is_corresponding":false},{"id":241088,"name":"Volker Thiel","orcid":"0000-0002-5783-0887","position":16,"is_corresponding":false},{"id":55415,"name":"Ulrich Martin","orcid":"0000-0003-1058-4540","position":17,"is_corresponding":false},{"id":620148,"name":"Daniela Niemeyer","orcid":"0000-0002-1897-6365","position":18,"is_corresponding":false},{"id":793124,"name":"Gisa Gerold","orcid":"0000-0002-1326-5038","position":19,"is_corresponding":false},{"id":636835,"name":"Dieter Beule","orcid":"0000-0002-3284-0632","position":20,"is_corresponding":false},{"id":57978,"name":"Christine Goffinet","orcid":"0000-0002-3959-004X","position":21,"is_corresponding":false},{"id":793117,"name":"Baxolele Mhlekude","orcid":"0000-0003-3696-2482","position":0,"is_corresponding":true}],"reference_count":108,"raw_metadata":null,"created_at":"2026-07-19T01:21:46.548301Z","pmid":"37747932","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}